ArticleJHLT open2026
Amiodarone use prior to cardiac transplant in children is associated with increased need for post-transplant chronotropic support.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of amiodarone prior to cardiac transplant in adults is associated with worse post-transplant outcomes. Data are scarce in pediatrics regarding the association of pre-amiodarone use with post-transplant outcomes. We aim to describe and compare pediatric post-transplant outcomes based on use of pre-transplant amiodarone at a large pediatric cardiac transplant center. Methods: We performed a retrospective cohort study of pediatric patients 18 years or younger who underwent cardiac transplant between 2015 - 2021. Pre-transplant amiodarone use was defined as use/administration of amiodarone within two weeks pre-transplant. Pre-transplant characteristics and post-transplant outcomes including mortality and markers of morbidity were compared between the two groups. Results: Six percent (10/156) of the study population were on amiodarone pre-transplant. There were no differences in mortality between the two groups. Severe primary graft dysfunction (PGD) incidence was higher in the pre-transplant amiodarone group (p = 0.04). The use of post-transplant isoproterenol (p = 0.01) and temporary pacing (p = 0.01) were higher in the pre-transplant amiodarone group. There was no association between either amiodarone dose or length therapy with post-transplant outcomes. Conclusions: Higher rates of PGD, increased use of isoproterenol, and need for temporary pacing post-transplant among patients receiving pre-transplant amiodarone suggests that amiodarone may contribute to inadequate chronotropy in the acute post-operative period. The need for chronotropic support occurred irrespective of amiodarone dose or length of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.